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Abstract
We recently reported a cardioselective and cumulative oxidation of cardiac mitochondrial DNA (mtDNA)
following subchronic administration of doxorubicin to rats. The mtDNA adducts persist for up to 5 weeks after
cessation of doxorubicin treatment. Since the evidence suggests that this persistence of mtDNA adducts cannot be
attributed to a lack of repair and replication, we investigated whether it might reflect a long-lasting stimulation of free
radical-mediated adduct formation. Male Sprague–Dawley rats received weekly s.c. injections of either doxorubicin
(2 mg/kg) or an equivalent volume of saline. Cardiac myocytes isolated from rats following 6 weekly injections of
doxorubicin expressed a much higher rate of reactive oxygen species (ROS) formation compared to saline controls.
This higher rate of ROS formation persisted for 5 weeks following the last injection. Associated with this was a
persistent depression of GSH in heart tissue, while protein-thiol content was not markedly altered. These data suggest
that the accumulation and persistence of oxidized mtDNA may be due, not to the stability of the adducts, but to
some as yet undefined toxic lesion that causes long-lasting stimulation of ROS generation by doxorubicin. This
persistent generation of ROS may contribute to the cumulative and irreversible cardiotoxicity observed clinically with
the drug. © 2001 Elsevier Science Ireland Ltd. All rights reserved.
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1. Introduction
Long-term administration of doxorubicin
(DOX), a potent antineoplastic agent for treating
various human tumors, causes a cumulative dose-
dependent cardiomyopathy. The mechanism of
this DOX-induced cardiotoxicity is attributed to
free radical generation, stimulation of lipid perox-
idation, and subsequent alteration of cellular
membrane integrity. This hypothesis is supported
by the reported cytoprotective effect of antioxi-
dants against DOX toxicity (Kimura et al., 2000;
Wang and Kang, 1999; Wu and Kang, 1998). An
increasing number of studies demonstrate that
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DOX causes a dose-dependent disruption of car-
diac mitochondrial structure and bioenergetic
function (Nicolay and De Kruijff, 1987; Papado-
poulou et al., 1999; Praet and Ruysschaert, 1993;
Solem et al., 1994, 1996), and implicate mitochon-
drial dysfunction in the pathogenesis of DOX-in-
duced cardiomyopathy. We hypothesize that
DOX-induced cardiotoxicity is mediated through
altered mitochondrial function caused by DOX-
induced free radical generation.
We recently demonstrated that DOX causes the
preferential accumulation of 8-hydrox-
ydeoxyguanosine (8OHdG) in cardiac mitochon-
drial DNA (mtDNA) (Palmeira et al., 1997).
Moreover, this cardioselective oxidation of mito-
chondrial DNA is cumulative with repeated dos-
ing and persists for 5 weeks after cessation of
DOX treatment (Serrano et al., 1999). The accu-
mulation and persistence of 8OHdG caused by
DOX is in accord with the irreversible cardiomy-
opathy observed clinically. Since expression of the
mitochondrial genome is essential to the integrity
of the respiratory chain, oxidation of mtDNA
may interfere with the expression of critical mito-
chondrial electron transport proteins, which
might underlie the pathogenesis of DOX
cardiomyopathy.
The formation of 8OHdG adducts is attributed
to reactive oxygen species. Indeed, a strong corre-
lation has been characterized between the rate of
generation of hydroxyl free radicals in submito-
chondrial particles and the occurrence of 8OHdG
adducts to the mitochondrial genome (Giulivi et
al., 1995). Although a number of initial studies
reported deficiencies in mtDNA repair mecha-
nisms that might explain the persistence of
mtDNA adducts (LeDoux et al., 1992; Miyaki et
al., 1977; Niranjan et al., 1981; Stairs et al., 1983),
recent evidence demonstrates that mitochondria
are capable of repairing oxidative damage to
mtDNA (Salazar and Van Houten 1997; Yakes
and Van Houten, 1997). Moreover, mtDNA ad-
ducts can be eliminated by mitochondrial
turnover. Thus, the persistence of mtDNA ad-
ducts is not likely attributable to the stability of
the adducts in vivo. Therefore, we questioned
whether the persistence of 8OHdG adducts might
reflect prolonged stimulation of ROS generation
and oxidative stress that continues long after ter-
mination of drug treatment.
2. Materials and methods
2.1. Materials
Doxorubicin was purchased from Pharmacia &
Upjohn Co. (Kalamazoo, MI). 5-(and 6-)-
chloromethyl-2,7-dichlorodihydro-fluorescein di-
acetate (CM-H2DCFDA) was purchased from
Molecular Probes (Eugene, OR). All other chemi-
cals were of analytical grade and obtained from
common commercial sources.
2.2. Animals
Male Sprague–Dawley rats (Harlan Labs,
Madison, WI) weighing 1755 g were divided
randomly between treatment groups and main-
tained in AAALAC-accredited, climate-controlled
facilities and allowed free access to food (Purina
Chow) and water. Rats received 6 weekly s.c.
injections of either doxorubicin (2 mg/kg) or an
equivalent volume of saline (1 ml/kg). The ani-
mals were killed by decapitation 1 or 5 weeks
after the last injection. The hearts were excised
immediately to isolate cardiac myocytes for deter-
mination of ROS generation or frozen in liquid
nitrogen and stored at −80°C until assayed for
GSH and protein-thiol.
2.3. Determination of reactie oxygen species
(ROS)
ROS were determined fluorometrically using a
Labsystems type 374 plate-reader fluorometer.
Cardiac myocytes were isolated as previously de-
scribed (Solem et al., 1996). Isolated cardiac my-
ocytes were suspended in Rosewell Park
Memorial Institute (RPMI) medium at a density
of 5×105 live cells/ml. Cells were loaded with 50
M CM-H2DCFDA (prepared in DMSO) for 15
min at 37°C. Cell suspension (200 l; 105 cells)
were loaded into a 96-well plate. The formation of
the oxidized derivative of CM-H2DCF, was moni-
tored fluorimetrically at an excitation wavelength
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485 nm and an emission wavelength 538 nm. The
fluorescence was monitored for 30 min to calculate
the rate of ROS formation. The results were
expressed as fluorescence intensity increase per 105
cells per 10 min.
2.4. Analysis of GSH and protein-thiol
Determination of GSH was performed by a
modified fluorometric method (Hissin and Hilf,
1976). Rat heart tissue (250 mg) was homogenized
on ice using a Polytron homogenizer. The solution
used for homogenization consisted of 3.75 ml of
phosphate–EDTA buffer (0.1 M sodium phos-
phate, 5 mM EDTA, pH 8.0) and 1 ml of 25%
HPO3. The total homogenate was centrifuged at
4°C at 100000×g for 30 min. The supernatant was
removed for the assay of GSH, and the pellet was
used for determining protein-thiol content. For the
GSH assay, 10 l of the 100000×g supernatant
was added to 1.89 ml of phosphate–EDTA buffer,
and 100 l of 1 mg/ml o-phthalaldehyde (OPT)
solution (prepared in methanol). After thorough
mixing and incubation at room temperature for 15
min, 250 l of the solution was loaded into a 96-well
plate. Fluorescence at 405 nm was measured with
the excitation at 320 nm. Quantification of GSH
was obtained by employing commercial GSH stan-
dards. The results are expressed as mole GSH per
gram wet heart weight.
Determination of protein-thiol was performed
by a modification of the method of Riddles et al.
(1979). Briefly, the 100000×g pellet was resus-
pended in 2 ml phosphate buffer. To 0.5 ml of this
mixture, 4.5 ml phosphate buffer and 50 l of 10
mM 5,5-dithiobis-(2-nitrobenzoic acid) (DTNB)
was added. After thorough mixing and incubation
at room temperature in the dark for 15 min, the
solution was transferred to a cuvette. Absorbance
was measured at 412 nm using a Beckman DU 7400
spectrophotometer. The results are expressed as
mole 2-nitro-5-thiobenzoic acid (TNB) per gram
wet heart weight using a coefficient of 13600 M−1
cm−1.
2.5. Statistical analysis
All data are expressed as the meanSE for
two–five separate animals. Differences between
DOX and saline treatment were analyzed using the
Student t test. A probability of P0.05 served as
the criterion for statistical significance.
3. Results
The initial weights for saline and DOX groups
were 1764 and 1752 g, respectively. As shown
in Table 1, 6 weeks of DOX treatment retarded rat
body weight gain by about 10% compared to
controls. This was associated with a 15% decrease
in ventricular heart weight as compared to saline-
treated rats but there was no difference in the heart
weight to body weight ratio between DOX-treated
and saline-treated rats. Moreover, the decrease in
both body weight and heart weight of DOX-treated
rats persisted for a 5 week period after cessation of
DOX treatment: DOX rats maintained body
weight, while control rats continued to gain weight
(Table 1).
The yield and viability of cardiac myocytes were
not different between 6 week DOX and saline-
treated rats. However, both cell yield and cell
viability decreased markedly after 5 weeks recovery
following the sixth injection (cell yields
Table 1
Rat body and heart weight (g)a
DOXSaline
6+1b
38729Body weight (Bw) 34623c
1.420.06cHeart weight (Hw) 1.660.12
0.430.01 0.410.01Ratio (Hw/Bw)×100
6+5wb
4202Body weight (Bw) 3204c
Heart weight (Hw) 1.220.09c1.570.05
Ratio (Hw/Bw)×100 0.370.02 0.380.04
a Data represent the mean  SE for four animals.
b 6+1w and 6+5w represent samples from rats killed 1 or 5
weeks, respectively, following the last of 6 weekly injections of
DOX or saline.
c Significant difference compared to saline control at P
0.05.
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Fig. 1. DOX-induced ROS formation in cardiac myocytes.
Rats received 6 weekly injections of DOX (2 mg/kg) or saline.
6+1w and 6+5w represent rats killed 1 or 5 weeks, respec-
tively, after the last injection. Reactive oxygen species (ROS)
were estimated fluorometrically using the probe CM-
H2DCFDA, and expressed as fluorescent intensity increase per
105 cells per 10 min. Data represent the meanSE of mea-
surements from three 6+1w rats and two 6+5w rats, respec-
tively. *, significant difference compared to saline control at
P0.05.
4. Discussion
In agreement with our previous findings (Solem
et al., 1994, 1996), both body weight and heart
weight were significantly less in 6-week DOX-
treated rats compared to controls. Moreover, in
the present study we found that the decrease in
both body weight and heart weight persisted for a
5-week period after cessation of DOX treatment.
This suggests an irreversible, and possibly pro-
gressive pathogenic process.
In correlation with the effect on body weight
gain, we found a persistent stimulation of ROS
formation. This persistent ROS formation is of
particular importance in elucidating the mecha-
nism of DOX-induced cardiotoxicity, as it corre-
lates well with our recent finding of the
persistence of oxidized mtDNA adducts. The ac-
cumulation of mtDNA 8OhdG adducts has been
ascribed to ROS generation (Giulivi et al., 1995).
Despite initial reports of deficiencies in mtDNA
repair enzymes, recent studies demonstrate that
oxidative DNA damage can be repaired in mito-
Fig. 2. GSH content in heart tissue harvested from DOX/sa-
line treated rats. Rats received 6 weekly injections of DOX (2
mg/kg) or saline. 6+1w and 6+5w are defined in Fig. 1.
Determination of GSH was performed by a modified fluoro-
metric method using OPT. Values are expressed as mole
GSH per gram wet heart weight. Data represent the mean 
SE of measurements from five separate rats. *, significant
difference compared to saline control at P0.05.
for saline and DOX-treated rats are 4.10.2×
106 and 4.41.9×105 live cells per animal, with
a viability of 74.51.5 and 58.53.5%, respec-
tively). Myocytes isolated from rats treated for
6-weeks with DOX, expressed a dramatically
higher rate of ROS formation compared to con-
trol (about three fold). Interestingly, the higher
rate of ROS formation was evident even 5 weeks
following the last injection of DOX (Fig. 1).
The effect of DOX on cardiac GSH is presented
in Fig. 2. GSH in heart tissue from 6-week DOX-
treated rats was significantly diminished, about
20% less compared to saline controls. The GSH
content remained lower than control 5 weeks after
discontinuation of DOX treatment (Fig. 2). There
was no statistical difference in cardiac GSH con-
tent between the two control groups.
The effect of DOX on protein-thiol is presented
in Fig. 3. No differences in protein-thiol content
were found in heart tissues between DOX and
saline-treated rats.
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Fig. 3. Protein-SH content in heart tissue harvested from
DOX/saline treated rats. Rats received 6 weekly injections of
DOX (2 mg/kg) or saline. 6+1w and 6+5w are defined in
Fig. 1. The protein-SH was determined spectrophotometrically
at 412 nm by using 5,5-dithiobis(2-nitrobenzoic acid). Values
are expressed as mole TNB per gram wet heart tissue. Data
represent the meanSE of measurements from five separate
rats.
residual doxorubicin is undetectable 7 days fol-
lowing the last injection (Solem et al., 1994, 1996).
Therefore, we propose the alternate hypothesis
that this persistent ROS generation occurs as a
consequence of damage to the mitochondria
caused by DOX. Indeed, it is well established that
inhibition of the mitochondrial electron transport
chain in vitro by antimycin A, results in a signifi-
cant increase in the mitochondrial free radical
production (Boveris and Chance, 1973; Turrens
and Boveris, 1980; Turrens et al., 1982, 1985). In
a recent study, Esposito et al. (1999) demon-
strated that inhibition of oxidative phosphoryla-
tion by knocking out the adenine nucleotide
translocator gene also results in increased ROS
production and consequent damage to the
mtDNA. Accordingly, it is feasible that repetitive
DOX dosing causes some type of permanent im-
pairment damage that leads to the persistent stim-
ulation of ROS generation. For example, this
could be a manifestation of the biogenesis of
poorly coupled mitochondria (Esposito et al.,
1999; Jeyaseelan et al., 1997; Papadopoulou et al.,
1999) or the conversion of xanthine dehydroge-
nase to xanthine oxidase (Gustafson et al., 1991).
Because of its proximity to oxidative phospho-
rylation in the mitochondrial inner membrane,
mtDNA is highly susceptible to oxidation by ROS
and the oxidized DNA may directly contribute to
mitochondrial genomic mutations. Unlike nuclear
DNA, however, mtDNA encodes rRNAs, tRNAs
and mitochondrial proteins with no nonsense se-
quences, except for a small region involved in the
regulation of replication and translation of
mtDNA. Thus, it is highly probable that any
mutation in the mtDNA will result in a pheno-
typic response. This hypothesis is supported by a
number of studies which show that damage to
mtDNA causes a decrease in the levels of mito-
chondrial transcripts (Andreu et al., 1998; Calleja
et al., 1993). Indeed, it has been demonstrated
that DOX suppresses the expression of several
mitochondrial genes, including genes encoding cy-
tochrome c oxidase (Papadopoulou and Tsift-
soglou, 1996; Papadopoulou et al., 1999) and the
adenine nucleotide translocator (Jeyaseelan et al.,
1997). All these effects may lead to substantial
alterations in the synthesis of mitochondrial
chondria (Salazar and Van Houten, 1997; Yakes
and Van Houten, 1997). Moreover, the pathways
that are suggested to operate in the nucleus and
mitochondria to repair oxidative DNA damage
appear to be similar (Driggers et al., 1996). Ac-
cordingly, the accumulation of mtDNA adducts
cannot be fully explained by the lack of repair of
oxidized mtDNA. Indeed, in a previous study we
found that 8OHdG adducts to cardiac mitochon-
dria decrease to control values 2 weeks following
a single injection of DOX (Palmeira et al., 1997),
which suggests either the repair or replacement of
oxidized mtDNA. The persistence of mtDNA ad-
ducts induced by DOX may, therefore, more
likely represent a situation where the formation of
8OHdG is continuously stimulated and exceeds
the limited capacity to repair these adducts.
Indeed, it is well established that DOX induces
ROS generation due to the univalent reduction to
its semiquinone free radical intermediate. How-
ever, it isn’t likely that the persistent ROS genera-
tion 5 weeks after cessation of DOX treatment
reflects redox cycling of the drug, because the
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proteins. Thus, following the last DOX dosing, it
is possible that the newly synthesized dysfunc-
tional mitochondria may continue to generate
high levels of ROS, which in turn provide a
continuous source of oxidation of mtDNA.
The overall antioxidant defense system is also
an important factor determining the fate of DOX-
induced ROS. It has been suggested that the
occurrence of oxidative injury reflects stimulated
generation of ROS that exceeds the capacity of
antioxidant defense systems. GSH is the most
important antioxidant against ROS. In agreement
with previous reports that DOX treatment de-
creases GSH (Gustafson et al., 1993; Olson et al.,
1980; Yin et al., 1998), we found that GSH is
diminished in heart tissue from 6-week DOX-
treated rats (c.a., 20% less than control) and
remained suppressed 5 weeks after discontinua-
tion of DOX treatment (Fig. 2). This persistently
lower GSH is consistent with the persistent ROS
formation. However, there was no difference in
protein-thiol content of heart tissue between DOX
and saline-treated rats. This might be due to the
effect of GSH, which though depleted, may still
provide sufficient reduction of heart tissue
protein-thiols against ROS-induced oxidation. In
addition, there might be compensatory actions of
other antioxidant systems in response to this in-
creased oxidative stress in the cells. For example,
it has been reported that DOX treatment in-
creases metallothionein content and catalase ac-
tivity in heart tissues (Yin et al., 1998).
In summary, we demonstrate a higher rate of
ROS formation in cardiac myocytes isolated from
rats following 6 weekly injections of DOX, and
that this enhanced ROS generation persists for up
to 5 weeks after the last injection. This correlates
well with our previous finding of the cumulative
and persistent oxidation of cardiac mtDNA. As-
sociated with the sustained high rate of ROS
formation is a persistent depression of GSH in
heart tissue. The enhanced generation of ROS
may directly damage mitochondria or alter mito-
chondrial genomic expression, thus altering the
synthesis of proteins associated with the mito-
chondrial electron transport chain. All of these
events might lead to a catastrophic bioenergetic
dysfunction of mitochondria in a feed-forward
cascade, eventually accounting for the cumulative
and progressive pathogenesis of DOX-induced
cardiomyopathy.
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